DOD, Rare Cancers, Idea Development Award | HT9425 23 RCRP IDA

Opportunity Information: Apply for HT9425 23 RCRP IDA

The FY23 Department of Defense Rare Cancers Research Program (RCRP) Idea Development Award is a competitive funding opportunity designed to push forward early-stage, high-impact research ideas aimed at reducing deaths and suffering from rare cancers. The program is looking for concepts that are not yet fully mature but are far enough along to generate meaningful, actionable data that could open up new directions in the field. In practice, this award is meant to help investigators take a strong, well-reasoned scientific idea and develop it into a body of evidence that can drive major advances, accelerate discovery, and ultimately improve outcomes for people diagnosed with rare cancers.

A central requirement of the opportunity is that the application must be built around a clearly stated, testable hypothesis supported by strong scientific rationale. The proposal should show careful reasoning grounded in what is already known, including a critical reading of the existing literature, and it should explain why the approach is likely to work. While the award supports projects in the earlier stages of development, it is not intended for purely speculative concepts. Applicants are expected to include preliminary data that demonstrate feasibility and support the proposed hypothesis and methods. Importantly, the preliminary data must be tied to a disease-specific rationale, and it may include correlative work linked to ongoing clinical research. At the same time, the program is flexible about where those initial data come from: they do not have to be generated in the exact rare cancer type or subtype being proposed, and they may come from outside the rare cancers field as long as the applicant convincingly explains how the evidence translates and why it is relevant.

The defining feature of the Idea Development Award is impact. Reviewers are looking for projects that are not only scientifically sound but also have a high potential to meaningfully change the landscape for rare cancers, whether by enabling a new therapeutic direction, identifying a key mechanism, improving diagnosis or stratification, or creating a strong platform for subsequent translational or clinical work. The opportunity explicitly emphasizes that scientific excellence alone is not enough if the proposal does not make a compelling case for significant impact on rare cancers. Applicants are expected to clearly and directly articulate how their project could lead to major advancements and why the outcomes would matter for patients, clinicians, and the broader rare cancers research community.

From an administrative standpoint, this is a discretionary federal funding opportunity offered by the Department of Defense, Department of the Army, through USAMRAA. The funding instrument can be either a grant or a cooperative agreement, and the activity category falls under science and technology and other research and development (CFDA 12.420). Eligibility is described as unrestricted, meaning it is broadly open to many types of organizations, subject to any clarifications that might appear in the full eligibility text of the announcement. The opportunity was posted on April 19, 2023, with an original closing date of September 29, 2023, and the program anticipated making about 15 awards. The listed award ceiling is shown as 0, which typically signals that the maximum is not specified in the summary field and that applicants should rely on the full announcement for budget expectations, constraints, and any limits tied to project scope or period of performance.

Overall, this award is best suited for teams that have a promising, innovative research direction with enough early evidence to justify moving forward, and who can explain, in concrete terms, how the work could create a step change for rare cancers rather than a small incremental gain. The strongest applications will connect the dots between preliminary findings, a focused and testable hypothesis, a feasible research plan, and a clear story of how the results could unlock new avenues or accelerate progress toward reducing mortality and suffering in rare cancer populations.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DOD, Rare Cancers, Idea Development Award" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Apr 19, 2023.
• Applicants must submit their applications by Sep 29, 2023. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 15 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for HT9425 23 RCRP IDA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: